share_log

The One-year Decline in Earnings Might Be Taking Its Toll on Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Shareholders as Stock Falls 5.0% Over the Past Week

The One-year Decline in Earnings Might Be Taking Its Toll on Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Shareholders as Stock Falls 5.0% Over the Past Week

由於該股在過去一週下跌5.0%,一年的收益下降可能會給浙江康恩博藥業有限公司(上海證券交易所代碼:600572)的股東造成損失
Simply Wall St ·  2023/10/19 13:40

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could make more than that. To wit, the Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) share price is 23% higher than it was a year ago, much better than the market decline of around 6.4% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! Zooming out, the stock is actually down 3.2% in the last three years.

如果你想在股市增加財富,你可以通過購買指數基金來實現。但如果你選擇了正確的個股,你可以賺得更多。也就是說,浙江康巴藥業有限公司(上海證券交易所股票代碼:600572)股價較一年前高出23%,遠好於同期約6.4%的市場跌幅(不包括股息)。如果它能夠長期保持這種優異的表現,投資者將會做得非常好!縮小後,股票實際上是降下來最近三年的增長率為3.2%。

Although Zhejiang CONBA PharmaceuticalLtd has shed CN¥694m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

儘管浙江康巴藥業股份有限公司本週市值縮水6.94億元,但讓我們來看看其較長期的基本面趨勢,看看它們是否推動了回報。

Check out our latest analysis for Zhejiang CONBA PharmaceuticalLtd

查看我們對浙江康巴製藥有限公司的最新分析

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然有效市場假說繼續被一些人傳授,但事實證明,市場是過度反應的動態系統,投資者並不總是理性的。一種不完美但簡單的方法來考慮市場對一家公司的看法是如何改變的,那就是將每股收益(EPS)的變化與股價走勢進行比較。

Over the last twelve months, Zhejiang CONBA PharmaceuticalLtd actually shrank its EPS by 66%.

在過去的12個月裡,浙江康巴製藥有限公司的每股收益實際上縮水了66%。

Given the share price gain, we doubt the market is measuring progress with EPS. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

考慮到股價的上漲,我們懷疑市場是否在衡量每股收益的進展。由於每股收益的變化似乎與股價的變化沒有相關性,因此值得看看其他指標。

Revenue was pretty stable on last year, so deeper research might be needed to explain the share price rise.

營收與去年相比相當穩定,因此可能需要更深入的研究來解釋股價上漲的原因。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收益和收入隨時間的變化情況(如果您點擊該圖,您可以看到更多詳細資訊)。

earnings-and-revenue-growth
SHSE:600572 Earnings and Revenue Growth October 19th 2023
上海證交所:600572收益和收入增長2023年10月19日

It is of course excellent to see how Zhejiang CONBA PharmaceuticalLtd has grown profits over the years, but the future is more important for shareholders. You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

看到浙江康巴製藥有限公司多年來如何實現利潤增長,當然是件好事,但對股東來說,未來更重要。你可以看到它的資產負債表是如何隨著時間的推移而加強(或削弱)的免費互動式圖形。

What About Dividends?

那股息呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Zhejiang CONBA PharmaceuticalLtd, it has a TSR of 25% for the last 1 year. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

重要的是要考慮任何給定股票的總股東回報以及股價回報。TSR包括任何剝離或貼現融資的價值,以及任何股息,基於股息再投資的假設。因此,對於支付豐厚股息的公司來說,TSR往往比股價回報高得多。以浙江康巴製藥有限公司為例,它在過去一年的TSR為25%。這超過了我們之前提到的它的股價回報。這在很大程度上是其股息支付的結果!

A Different Perspective

不同的視角

It's good to see that Zhejiang CONBA PharmaceuticalLtd has rewarded shareholders with a total shareholder return of 25% in the last twelve months. Of course, that includes the dividend. There's no doubt those recent returns are much better than the TSR loss of 2% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Zhejiang CONBA PharmaceuticalLtd you should know about.

很高興看到浙江康巴製藥有限公司在過去的12個月裡以25%的總股東回報回報了股東。當然,這包括股息。毫無疑問,最近的回報率遠遠好於TSR在過去五年中每年2%的損失。這讓我們有點警惕,但這家企業可能已經扭轉了命運。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。例如,考慮一下風險。每家公司都有它們,我們已經發現浙江康巴藥業有限公司2個警示標誌你應該知道。

Of course Zhejiang CONBA PharmaceuticalLtd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然了浙江康巴藥業股份有限公司可能不是買入的最佳股票那就是。所以你可能想看看這個免費成長型股票的集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論